Demographic characteristics of efficacy outcome cohort
| | Cohort (n = 97) |
|---|---|
| Sex, n (%) | |
| Male | 58 (60) |
| Race, n (%) | |
| White | 68 (70) |
| Black, African American | 21 (22) |
| Asian | 3 (3) |
| American Indian | 2 (2) |
| Native Hawaiian | 1 (1) |
| >1 race | 2 (2) |
| Ethnicity, n (%) | |
| Hispanic or Latino | 18 (19) |
| Not Hispanic or Latino | 79 (81) |
| Genetic/syndromic etiology, n (%) | |
| 22q11.2 deletion | 36 (37) |
| CHARGE/CHD7 mutationa | 24 (25) |
| FOXN1 mutation | 2 (2) |
| PAX1 mutation | 1 (1) |
| TBX2 mutation | 1 (1) |
| Diabetic embryopathy | 21 (22) |
| No known mutation/syndrome | 12 (12) |
| Syndromic comorbidities, n (%) | |
| Choanal atresia | 11 (11) |
| Cleft palate or submucous cleft | 17 (17) |
| Coloboma | 19 (20) |
| Congenital cardiac anomaly | 87 (90) |
| Deafness or ear pinnae anomalies | 50 (51) |
| Dysmorphic facies | 45 (46) |
| Tracheal anomalies | 25 (26) |
| Genital hypoplasia | 12 (12) |
| Hypocalcemia | 82 (84) |
| Anal/rectal anomalies | 6 (6) |
| Renal anomalies | 26 (27) |
| Autoimmunity, n (%) | |
| Rashb | 37 (38) |
| Symptomatic GVHDc | 2 (2) |
| Thrombocytopenia | 10 (10) |
| Neutropenia | 6 (6) |
| Autoimmune hemolytic anemia | 6 (6) |
| Hypothyroid | 6 (6) |
| Age at time of implantation (months) | |
| Median (Q1; Q3) | 9 (4; 14) |
| Minimum, maximum | 1, 53 |
| | Cohort ( |
|---|---|
| | |
| Male | 58 (60) |
| | |
| White | 68 (70) |
| Black, African American | 21 (22) |
| Asian | 3 (3) |
| American Indian | 2 (2) |
| Native Hawaiian | 1 (1) |
| >1 race | 2 (2) |
| | |
| Hispanic or Latino | 18 (19) |
| Not Hispanic or Latino | 79 (81) |
| | |
| 22q11.2 deletion | 36 (37) |
| CHARGE/ | 24 (25) |
| 2 (2) | |
| 1 (1) | |
| 1 (1) | |
| Diabetic embryopathy | 21 (22) |
| No known mutation/syndrome | 12 (12) |
| | |
| Choanal atresia | 11 (11) |
| Cleft palate or submucous cleft | 17 (17) |
| Coloboma | 19 (20) |
| Congenital cardiac anomaly | 87 (90) |
| Deafness or ear pinnae anomalies | 50 (51) |
| Dysmorphic facies | 45 (46) |
| Tracheal anomalies | 25 (26) |
| Genital hypoplasia | 12 (12) |
| Hypocalcemia | 82 (84) |
| Anal/rectal anomalies | 6 (6) |
| Renal anomalies | 26 (27) |
| | |
| Rash | 37 (38) |
| Symptomatic GVHD | 2 (2) |
| Thrombocytopenia | 10 (10) |
| Neutropenia | 6 (6) |
| Autoimmune hemolytic anemia | 6 (6) |
| Hypothyroid | 6 (6) |
| | |
| Median (Q1; Q3) | 9 (4; 14) |
| Minimum, maximum | 1, 53 |